News & Updates

FVC decline predicts death in patients with progressive fibrosing ILD
FVC decline predicts death in patients with progressive fibrosing ILD
04 Apr 2022 byStephen Padilla

Patients with idiopathic pulmonary fibrosis (IPF) exhibit a similar course of lung injury with those having other forms of progressive fibrosing interstitial lung disease (ILD), reveals a study, which also shows the association of forced vital capacity (FVC) decline with short-term mortality in this population.

FVC decline predicts death in patients with progressive fibrosing ILD
04 Apr 2022
COPD, smoking aggravate complication risk after lung cancer resection
COPD, smoking aggravate complication risk after lung cancer resection
03 Apr 2022

Smoking and chronic obstructive pulmonary disease (COPD) worsen the risk of postoperative pulmonary complications after lung cancer resection, a recent study has found. Focusing on COPD treatment, rather than smoking cessation alone, may be a more optimal approach to improve postoperative outcomes in this population.

COPD, smoking aggravate complication risk after lung cancer resection
03 Apr 2022
Psychological, cachectic comorbidities up death risk, exacerbations in COPD
Psychological, cachectic comorbidities up death risk, exacerbations in COPD
31 Mar 2022

Individuals with potential chronic obstructive pulmonary disease (COPD) in the psychological and cachectic clusters appear to be at increased risk of mortality over 25 years of follow-up, according to a population-based Norwegian study. In addition, these clusters appear to increase the risk of severe COPD exacerbations.

Psychological, cachectic comorbidities up death risk, exacerbations in COPD
31 Mar 2022
Empagliflozin lowers mortality, cardiorenal events even in COPD presence
Empagliflozin lowers mortality, cardiorenal events even in COPD presence
28 Mar 2022 byJairia Dela Cruz

Among patients with type 2 diabetes mellitus and cardiovascular disease, those with concomitant chronic obstructive pulmonary disease (COPD) are at higher risk of mortality and adverse cardiorenal outcomes, including heart failure, according to post hoc analyses of the EMPA-REG OUTCOME trial. However, these outcomes can be prevented with empagliflozin treatment, regardless of the presence of COPD.

Empagliflozin lowers mortality, cardiorenal events even in COPD presence
28 Mar 2022